These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 19446719)

  • 21. CCR5 antagonists: host-targeted antiviral agents for the treatment of HIV infection, 4 years on.
    Westby M; van der Ryst E
    Antivir Chem Chemother; 2010 Apr; 20(5):179-92. PubMed ID: 20413825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The MOTIVATE trials: maraviroc therapy in antiretroviral treatment-experienced HIV-1-infected patients.
    van Lelyveld SF; Wensing AM; Hoepelman AI
    Expert Rev Anti Infect Ther; 2012 Nov; 10(11):1241-7. PubMed ID: 23113664
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and characterization of INCB9471, an allosteric noncompetitive small-molecule antagonist of C-C chemokine receptor 5 with potent inhibitory activity against monocyte migration and HIV-1 infection.
    Shin N; Solomon K; Zhou N; Wang KH; Garlapati V; Thomas B; Li Y; Covington M; Baribaud F; Erickson-Viitanen S; Czerniak P; Contel N; Liu P; Burn T; Hollis G; Yeleswaram S; Vaddi K; Xue CB; Metcalf B; Friedman S; Scherle P; Newton R
    J Pharmacol Exp Ther; 2011 Jul; 338(1):228-39. PubMed ID: 21459966
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists.
    Kondru R; Zhang J; Ji C; Mirzadegan T; Rotstein D; Sankuratri S; Dioszegi M
    Mol Pharmacol; 2008 Mar; 73(3):789-800. PubMed ID: 18096812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro.
    Maeda K; Nakata H; Koh Y; Miyakawa T; Ogata H; Takaoka Y; Shibayama S; Sagawa K; Fukushima D; Moravek J; Koyanagi Y; Mitsuya H
    J Virol; 2004 Aug; 78(16):8654-62. PubMed ID: 15280474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug safety evaluation of maraviroc for the treatment of HIV infection.
    Wasmuth JC; Rockstroh JK; Hardy WD
    Expert Opin Drug Saf; 2012 Jan; 11(1):161-74. PubMed ID: 22118500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
    Fätkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AI; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ; Jenkins TM; Medhurst C; Sullivan JF; Ridgway C; Abel S; James IT; Youle M; van der Ryst E
    Nat Med; 2005 Nov; 11(11):1170-2. PubMed ID: 16205738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maraviroc first-line therapy for HIV infection. Too risky.
    Prescrire Int; 2010 Nov; 19(110):252-4. PubMed ID: 21284357
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Baseline susceptibility of primary HIV-2 to entry inhibitors.
    Borrego P; Calado R; Marcelino JM; Bártolo I; Rocha C; Cavaco-Silva P; Doroana M; Antunes F; Maltez F; Caixas U; Barroso H; Taveira N
    Antivir Ther; 2012; 17(3):565-70. PubMed ID: 22293827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Computational study on the interaction between CCR5 and HIV-1 entry inhibitor maraviroc: insight from accelerated molecular dynamics simulation and free energy calculation.
    Bai Q; Zhang Y; Li X; Chen W; Liu H; Yao X
    Phys Chem Chem Phys; 2014 Nov; 16(44):24332-8. PubMed ID: 25296959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chemokine receptors and its importance in the replication cycle of human immunodeficiency virus: clinical and therapeutic implications].
    Azevedo-Pereira JM; Santos-Costa Q
    Acta Med Port; 2008; 21(5):497-504. PubMed ID: 19187693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CCR5 antagonist blocks metastasis of basal breast cancer cells.
    Velasco-Velázquez M; Jiao X; De La Fuente M; Pestell TG; Ertel A; Lisanti MP; Pestell RG
    Cancer Res; 2012 Aug; 72(15):3839-50. PubMed ID: 22637726
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The chemokine system and CCR5 antagonists: potential in HIV treatment and other novel therapies.
    Dhami H; Fritz CE; Gankin B; Pak SH; Yi W; Seya MJ; Raffa RB; Nagar S
    J Clin Pharm Ther; 2009 Apr; 34(2):147-60. PubMed ID: 19250135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment with CCR5 antagonists: which patient may have a benefit?
    Mueller MC; Bogner JR
    Eur J Med Res; 2007 Oct; 12(9):441-52. PubMed ID: 17933726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation.
    Alkhatib G; Locati M; Kennedy PE; Murphy PM; Berger EA
    Virology; 1997 Aug; 234(2):340-8. PubMed ID: 9268166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genotypic coreceptor analysis.
    Sierra S; Kaiser R; Thielen A; Lengauer T
    Eur J Med Res; 2007 Oct; 12(9):453-62. PubMed ID: 17933727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical studies with chemokine receptor-5 (CCR5)-inhibitors.
    Boesecke C; Pett SL
    Curr Opin HIV AIDS; 2012 Sep; 7(5):456-62. PubMed ID: 22832708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients.
    Seclén E; González Mdel M; Lapaz M; Rodríguez C; del Romero J; Aguilera A; de Mendoza C; Soriano V; Poveda E
    J Antimicrob Chemother; 2010 Dec; 65(12):2502-4. PubMed ID: 20940179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.